ARS Pharmaceuticals, Inc. SEC filings SPRY

ARS Pharmaceuticals, Inc. has 549 filings in SEC EDGAR's recent list, going back to Apr 12, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

ARS Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 29, 2026 —
DEF 14A Proxy statement Apr 29, 2026 Jun 24, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 25, 2025
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 20, 2024
DEFA14A Additional proxy material May 1, 2023 —
DEF 14A Proxy statement May 1, 2023 Jun 27, 2023
DEFA14A Additional proxy material Nov 2, 2022 —
DEFA14A Additional proxy material Oct 27, 2022 —
DEFA14A Additional proxy material Oct 27, 2022 —
DEFA14A Additional proxy material Oct 21, 2022 —
DEFM14A Filing Oct 6, 2022 —
PREM14A Filing Aug 11, 2022 Aug 11, 2022
DEFA14A Additional proxy material Jul 21, 2022 —
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 28, 2022 Jun 10, 2022
DEFA14A Additional proxy material Apr 22, 2021 —
DEF 14A Proxy statement Apr 22, 2021 Jun 4, 2021

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SPRY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1671858
Former names
Silverback Therapeutics, Inc. (until Nov 8, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.